retatrutide peptide

What is retatrutide peptide (LY3437943)?

Retatrutide (also written as LY3437943) is an investigational “triple agonist” studied for obesity and other metabolic indications. People often search terms like “what is retatrutide”, “eli lilly retatrutide”, or “retatrutide peptide” to understand what it is and why it’s in the news.

Important context: the FDA has warned that retatrutide is not a component of an FDA-approved drug and has not been found safe/effective for any condition. That’s why legitimate information comes primarily from peer-reviewed publications, sponsor updates, and official clinical trial registries.

If you’re organizing research workflows and lab documentation, you can browse: Research Essentials.

References (this section):

• FDA: Concerns with unapproved GLP-1 drugs used for weight loss (mentions retatrutide not FDA-approved)
• Drugs.com: Retatrutide status & regulatory history

How does retatrutide work? (triple hormone receptor agonist)

How does retatrutide work? Retatrutide is widely described as a triple hormone receptor agonist because it targets three signaling pathways: GLP-1, GIP, and the glucagon receptor (GCGR). You may also see search phrases like “retatrutide triple hormone receptor agonist obesity” or slang like “GLP 3 retatrutide” referring to this triple-target idea.

Why triple agonism is a research focus

• GLP-1 activity is studied for effects on appetite regulation and glucose-related endpoints.
• GIP activity is studied for complementary metabolic signaling in combination with GLP-1.
• Glucagon receptor activity is studied for possible effects on energy expenditure and lipid metabolism in certain models.

References (this section):

• NEJM (2023): Retatrutide Phase 2 trial in obesity (mechanism + outcomes context)
• Eli Lilly: Phase 2 retatrutide results published in NEJM

Retatrutide clinical trials (TRIUMPH program): what’s being studied

Searches like “retatrutide clinical trials” and “retatrutide trial sign up” usually point to the sponsor’s Phase 3 program (often referred to as the TRIUMPH program) plus other listings in official registries. Trial protocols define eligibility, endpoints, and oversight, and they can change over time—so registries are the most reliable place to verify details.

Example registry listing (obesity + cardiovascular disease)

One publicly listed Phase 3 study is NCT05882045 (TRIUMPH-3), which evaluates efficacy and safety in participants with obesity and established cardiovascular disease.

References (this section):

• ClinicalTrials.gov: NCT05882045 (TRIUMPH-3) — retatrutide (LY3437943)
• Lilly Trials: TRIUMPH-3 summary (LY3437943)

Retatrutide clinical trial results: weight loss & metabolic findings so far

People searching “retatrutide results”, “retatrutide weight loss”, or “retatrutide before and after” are usually looking for published outcomes. The most widely cited early dataset is a Phase 2 trial in adults with obesity/overweight without diabetes, published in 2023.

Phase 2 (obesity/overweight without diabetes): high-level takeaway

• Published and sponsor-reported data describe mean weight reduction up to 24.2% at 48 weeks in the highest tested dose group (study context matters; not a head-to-head comparison).
• Trial reports also describe adverse events and discontinuation rates within controlled protocols.

Phase 3 updates (topline sponsor communications)

Sponsor press releases have also shared Phase 3 topline updates (for example, TRIUMPH-4). These updates are not the same as full peer-reviewed publications, so treat them as preliminary until complete data are published.

References (this section):

• NEJM (2023): Phase 2 trial publication
• Eli Lilly: Phase 2 results (mentions 24.2% at 48 weeks as a secondary endpoint)
• Eli Lilly (Dec 2025): Phase 3 TRIUMPH-4 topline results announcement

Retatrutide side effects: what trials report (not medical advice)

Searches like “retatrutide side effects” and “side effects of retatrutide” usually refer to events reported in clinical trial publications and sponsor summaries. Trial reports describe a profile broadly consistent with incretin-based therapies, with gastrointestinal effects commonly noted, often during dose escalation.

Commonly reported adverse events in trial reports (non-exhaustive)

• Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) reported in controlled trials
• Decreased appetite
• Safety monitoring included additional endpoints and clinical assessments per protocol

Does retatrutide cause hair loss?

“Does retatrutide cause hair loss?” is a frequent search. Hair shedding can be reported with significant or rapid weight change in general. Determining whether it is related to a specific drug versus weight change, nutrition, or other factors requires clinical evaluation and patient-specific context.

References (this section):

• Eli Lilly: notes GI side effects commonly reported and often during dose escalation (Phase 2 summary)
• NEJM (2023): safety/adverse events in Phase 2 publication

Is retatrutide FDA approved? Availability, cost, and “where to get” questions

Is retatrutide FDA approved? No—retatrutide is not an FDA-approved medication for weight loss or any other condition at the time of writing. This is why queries like “retatrutide availability”, “when will retatrutide be available”, and “retatrutide availability and cost” are so common.

Retatrutide cost / price

Because retatrutide is investigational, there is no official retail retatrutide price (or “cost per month”) as an approved prescription medication. If someone sees “retatrutide for sale” online, it may be unapproved/unregulated—FDA has publicly warned about risks of unapproved GLP-1 drugs used for weight loss.

How to get retatrutide / where to get retatrutide (public-facing info)

If you’re searching “how to get retatrutide” or “retatrutide near me”, the safest legitimate route for humans is typically through authorized clinical trials and medical supervision (see official trial registries for recruitment and eligibility). This article does not provide instructions for personal use.

References (this section):

• FDA: risks/concerns with unapproved GLP-1 drugs (mentions retatrutide not FDA-approved)
• Drugs.com: retatrutide approval status and timeline context
• ClinicalTrials.gov: example Phase 3 registry listing (TRIUMPH-3)

Research documentation & quality: COA/SDS, identity testing, chain-of-custody

For legitimate laboratory work, documentation and quality controls matter more than marketing claims. If you’re comparing “retatrutide peptides” online (including discussions on retatrutide reddit), prioritize materials that come with COA and appropriate safety documentation (SDS), and ensure your institution’s SOPs are followed.

• COA: confirm identity/assay method, lot number, and reported purity (where applicable).
• SDS: review handling/storage guidance and hazards per institutional safety requirements.
• Chain-of-custody: record receipt, storage conditions, and access controls for auditability.

For lab workflow essentials, browse: Research Essentials and relevant categories like Tissue & Recovery Research.

For COA/SDS and batch documentation (research use only): retatrutide (LY3437943) listing → https://peptidesskin.com/products/reta

References (this section):

• FDA: safety concerns around unapproved weight-loss GLP-1 drugs (risk context for unregulated markets)

FAQ (keyword-aligned)

What does retatrutide do?

Retatrutide is designed to activate GLP-1, GIP, and glucagon receptors (“triple agonist”), and researchers study how that impacts metabolic endpoints in clinical trials.

Is retatrutide a peptide?

Retatrutide is commonly referred to online as a “peptide,” and it is an investigational molecule studied in clinical trials under the development code LY3437943.

Is retatrutide natural?

Retatrutide is a synthetic investigational compound developed for research and clinical trials—not a naturally occurring supplement.

All references

1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss
2. NEJM (2023): Retatrutide Phase 2 trial in obesity
3. Eli Lilly: Phase 2 retatrutide results published in NEJM
4. Eli Lilly (Dec 2025): Phase 3 TRIUMPH-4 topline results announcement
5. ClinicalTrials.gov: NCT05882045 (TRIUMPH-3)
6. Drugs.com: Retatrutide status & timeline
7. Lilly Trials: TRIUMPH-3 summary page